Acepodia Announces China NMPA Clearance of ACE723 IND, Advancing Clinical Development in the U.S. and China

Acepodia today announced that China’s National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for ACE723, the Company’s first antibody-drug conjugate (ADC) candidate developed using its proprietary Antibody-Dual-Drug Conjugate (AD2C) platform, for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC).

Following the U.S. Food and Drug Administration (FDA) clearance of the ACE723 IND on September 4, 2026, the NMPA clearance represents another important regulatory milestone for the program and further advances the clinical development of ACE723 in both the United States and China. ACE723 is the first candidate from Acepodia’s AD2C platform to advance into clinical development, reflecting the Company’s continued execution in translating its proprietary technology platforms into clinical-stage programs.

The Company plans to advance ACE723 into Phase 1 clinical development to evaluate its safety, tolerability, pharmacokinetics, and preliminary antitumor activity, while generating human clinical data to support the further development of ACE723 and the clinical validation of the AD2C platform.